Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Maves’ change of heart on ephedra

This article was originally published in The Tan Sheet

Executive Summary

Letter to FDA signed by former CHPA President and current American Medical Association Exec VP & CEO Michael Maves, MD, reiterates AMA's call for ephedrine alkaloid products to be removed from the market due to the number of related AERs. While Maves was at CHPA, the trade association opposed FDA's reliance on AERs in developing regulatory restrictions for ephedrine alkaloid products. However, in a Jan. 28 letter, Maves states "the number of AERs associated with dietary supplements containing ephedrine alkaloids is alarming"...
Advertisement

Related Content

Acetaminophen resolution

Topics

Advertisement
UsernamePublicRestriction

Register

PS093635

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel